Can Technology Cure Cancer?

We will offer in a year’s time a complete cure for cancer.

Improving Hopefulness

Breast Cancer Awareness

With 18.1 million new cases per year, more money is spent on cancer research than any other disease. Imagine trading your cancer “hope” ribbons for cancer “survivor” pins. What if you could run a 5K marathon, not to raise money for research but because you are healthy enough to participate? When facing a course of vigorous treatment, the last thing you need is false hope—a finish line that appears to keep moving further away.

A group of Israeli doctors is making assertions too bold to ignore. Accelerated Evolution Biotechnologies Ltd (AEBi) promises a brief, cheap and effective remedy for cancer within a year. Not just breast cancer—all cancer. While nearly everyone hopes the news is true, you can understand skepticism. Called MuTaTo (multi-target toxin), researchers say the drug is essentially “on the scale of a cancer antibiotic—a disruption technology of the highest order.”

More money is spent on cancer research than any other disease.

The chairman of the board of AEBi is Dan Aridor. He earned an MBA degree in finance. The company was incubated in ITEK and birthed in the year 2000 as a development-stage bio­pharma­­ceutical company engaged in discovery of therapeutic peptides.

AEBi CEO Dr. Ilan Morad is currently overseeing MuTaTo advancement. Morad said. “By using at least three targeting peptides on the same structure with a strong toxin, we made sure that the treatment will not be affected by mutations.”

Breast cancer target
Targeting breast cancer —Adobe Stock Image

According to Morad, the MuTaTo cancer treatment will eventually be tailored to each patient after obtaining a small biopsy. “The individual would then be administered exactly the molecule cocktail needed to cure his disease.” Without the debilitating side effects of chemo therapy, treatment should be complete within a few weeks. Is this the most wonderful or delusional news in cancer research?

Amid optimistic claims, three factors dilute enthusiasm:

  • Limited information has been published by researchers.
  • The technology is still under development.
  • Human trials have yet to begin.
  • Clinical trials last several years as they monitor adverse side effects and longevity.

”We hope that this approach…bears fruit and is successful. At the same time, we must always offer a note of caution that the process to get this treatment from mouse to man is not always a simple and uncomplicated journey,” says Len Lichtenfeld, MD, ACS chief medical officer for the American Cancer Society.

In an unrelated King’s College London lab study, scientists identified a molecule found naturally in the immune system that could kill cancer cells.

Exposing colorectal tumours to the β-galactoside-binding protein (βGBP) in a petri dish triggered the ‘suicide’ of malignant cells within 48 hours.

βGBP is a form of immunotherapy, also called biologic therapy. This type of cancer treatment boosts the body’s natural defences to fight cancer. Authors hope βGBP will be studied in trials in the near future.

In the interim, ribbons of all colors abound and tradi­tional cancer preven­tion and treat­ment plans apply. This can include main­taining a healthy lifestyle, avoiding exposure to known cancer-causing substances, and taking medicines or vaccines that can prevent cancer from developing. With all the research taking place world­wide, cancer remission is more common than ever before with early detection.

Read more now, view references, and receive monthly summary of articles within A Bit More Healthy news­letter via email.

You must be a logged in subscriber for full access. If recently logged in, manually refresh page for more content.

If logged in, manually refresh page for more content.

September 26, 2019 by Kevin RR Williams

Were we helpful today?

Comments are moderated before publishing.

Manage your custom avatar at gravatar.com